CHIOME BIOSCIENCE INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 123 JPY | 0.00% |
|
-3.15% | -8.89% |
| Apr. 01 | Chiome Bioscience Cancels License Agreements with ADC Therapeutics | MT |
| Feb. 13 | Chiome Bioscience Inc. Announces Entrustment Agreement with Takeda Pharmaceutical Company Limited | CI |
Income Statement Evolution (Annual data)
| Fiscal Period: |
|---|
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 Q3 | 2021 Q1 | 2021 Q3 | 2022 Q1 | 2022 Q3 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Net sales 1 | 139 | 246 | 157 | 128 | 155 | 169 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -345 | -155 | -435 | -486 | -260 | -225 |
| Operating Margin | -248.2% | -63.01% | -277.07% | -379.69% | -167.74% | -133.14% |
| Earnings before Tax (EBT) 1 | -352 | -149 | -434 | -491 | -255 | -226 |
| Net income 1 | -351 | -160 | -434 | -492 | -256 | -227 |
| Net margin | -252.52% | -65.04% | -276.43% | -384.38% | -165.16% | -134.32% |
| EPS 2 | -9.320 | -4.000 | -10.78 | -11.66 | -5.700 | -4.700 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/10/20 | 5/14/21 | 11/12/21 | 5/13/22 | 11/14/22 | 5/11/23 |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: |
|---|
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -8.89% | 43.53M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- 4583 Stock
- Financials Chiome Bioscience Inc.
